ALKS Q4 2020 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$280M-32.2% YoY

Gross Profit

$237M84.7% margin

Operating Income

-$31M-11.0% margin

Net Income

-$43M-15.2% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

$67M

Free Cash Flow

$62M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$883M

Stockholders' Equity

$1.1B

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$280M	$413M	-32.2%
Gross Profit	$237M	$366M	-35.3%
Operating Income	-$31M	-$10M	-209.3%
Net Income	-$43M	-$5M	-696.5%

Revenue Segments

Product

$149M100%

Research And Development

$141,0000%